SAB BIOTHERAPEUTICS, INC. Accrued Investment Income Receivable
SAB BIOTHERAPEUTICS, INC. (SABS) had Accrued Investment Income Receivable of $1.84 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2026-08-06
- 2026-06-30: Accrued Investment Income Receivable $1.84M.
- 2026-03-31: Accrued Investment Income Receivable $1.56M.
- 2025-12-31: Accrued Investment Income Receivable $947.00K; Accrued Investment Income Receivable as first filed $946.78K.
- 2025-09-30: Accrued Investment Income Receivable $559.95K.
| Period end | Accrued Investment Income Receivable | Accrued Investment Income Receivable as first filed |
|---|---|---|
| 2026-06-30 | $1.84M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.56M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $947.00K 10-Q · filed 2026-08-06 | $946.78K 10-K · filed 2026-03-09 |
| 2025-09-30 | $559.95K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $21.39K 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $54.95K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $97.05K 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $224.92K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $193.23K 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |